San­doz joins up with B2B phar­ma to com­mer­cial­ize six biosim­i­lars in the US

No­var­tis sub­sidiary San­doz has joined up with B2B phar­ma Adal­vo in a dis­tri­b­u­tion and col­lab­o­ra­tion agree­ment for six un­named biosim­i­lar prod­ucts in the US, the com­pa­nies an­nounced Thurs­day.

San­doz now has the ex­clu­sive rights to com­mer­cial­ize the Adal­vo an­ti­fun­gals and an­tibi­otics, on­col­o­gy and pul­monary ther­a­peu­tics. The gener­ic and biosim­i­lar gi­ant ex­pects some of these launch­es to oc­cur in 2024 with a mar­ket size of around $3 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER